Navigation Links
Bavarian Nordic Has Signed Contract With an EU Country for the Delivery of IMVAMUNE(R)
Date:9/15/2009

KVISTGAARD, Denmark, September 15 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed.

This marks the first time Bavarian Nordic enters a contract with an EU country for the delivery of IMVAMUNE(R), and it demonstrates that there exists a real demand inside of EU for new and safer smallpox vaccines for preparedness stockpiles.

This contract does not affect the company's expectations for the 2009 full year results.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "Entering the first contract with an EU country on IMVAMUNE(R) demonstrates the need for new and safer smallpox vaccines. We have a continued ongoing positive dialogue with governments in and outside the EU, and we expect that this will lead to several smaller contracts. When we expectedly receive the approval from the US authorities to initiate the delivery of IMVAMUNE(R) under the RFP-3 contract for 20 million doses, this will be an important message to other governments currently considering to stockpile IMVAMUNE(R)."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bavarian Nordic A/S - Half Year Interim Report 2009
2. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
3. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
4. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
5. Bavarian Nordic Publishes its Annual Results 2008
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordics Case Against Oxford BioMedica
8. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
9. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
10. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
11. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/31/2015)... 31, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has filed its Annual ... Exchange Commission. The filed Form 20-F includes audited financial ... The Form 20-F can be accessed by visiting the ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... September 20, 2011 Silence Therapeutics plc ... leading global RNA interference (RNAi) therapeutics company, today announces ... with immediate effect. He will be based at Silence,s ... brings more than 20 years experience in corporate and ...
... be the nation,s next "Strontium Valley"? The University of Pittsburgh ... the National Science Foundation and the Nanoelectronics Research Initiative (NRI) ... kind of computer out of the lab and into the ... Levy, a professor of physics and astronomy in Pitt,s School ...
... Imagenetix, Inc. (OTCBB: IAGX) announced today that it received ... out of its pending dispute with former distributor TriPharma, ... pending before a private arbitrator and is conducted under ... in San Diego, California.  The interim award against the ...
Cached Biology Technology:Appointment of Chief Executive Officer 2Appointment of Chief Executive Officer 3Appointment of Chief Executive Officer 4Post-silicon computing 2Post-silicon computing 3Post-silicon computing 4
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... Technologies Inc. have signed a cooperative research and development ... Imaging Technologies, FlowCAM instrument to detect and document quagga ... spread of mussels throughout the western United States has ... hydropower generation functions as well as create long-term ecological ...
... Mass. -- A major challenge for cancer biologists is figuring ... a cancer cell are most important for driving the cancer,s ... MIT scientists have now pinpointed a gene that appears to ... of lung cancer accounting for about 15 percent of lung ...
Cached Biology News:Reclamation signs research agreement to improve quagga and zebra mussel larvae detection 2New lung-cancer gene found 2
... time consuming and inaccurate comparison of the entire ... of the sample when compared to the wild ... as a sharp peak. Accuracy of the ... 99%, with sensitivity to greater than 5% of ...
... is used to coat the inner wall of ... source of the DNA that enters target cells ... The station includes a tubing support cylinder, power ... nitrogen regulator hose, two 0.1875 inch barb-to-male Luer-Lok ...
... Helios gene gun low-pressure system, 220-240 V, is ... cells. This handheld device employs an adjustable helium ... gold microcarriers from the inner wall of a ... system can be used for in situ, in ...
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
Biology Products: